RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:3437

Vogt-Koyanagi-Harada disease

low confidenceDisorder

Also known as: Uveomenigitic syndrome

Publications

3,343

Trials

5

Interventional, condition-specific

Researchers

883

Distinct authors in sample

Gene link

—

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare bilateral granulomatous panuveitis characterized by an acute phase with serous retinal detachments associated with neurological (meningitis) and auditory alterations which, in case of delayed (>3-4 weeks) or insufficient treatment, evolves into a chronic phase with chronic anterior uveitis and retinal atrophic lesions (Dalen-Fuchs nodules and sunset glow fundus) associated with dermatological alterations. The disease is marked by increased choroidal inflammatory activity.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (3)

Harada's disease · Vogt-Koyanagi syndrome · uveomeningoencephalitic syndrome

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    3,343 matched papers (1,758 in last 10 years) Source

  3. Phenotype characterisedPresent

    39 HPO annotations (e.g. Cataract; Short stature; Posterior subcapsular cataract) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPresent

    5 matched on ClinicalTrials.gov (1 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

39

Associated phenotypes · MONDO:0018092

  • Cataract
  • Short stature
  • Posterior subcapsular cataract
  • Ocular hypertension
  • Retinal nerve fiber edema

Showing 5 of 39 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

23

Drugs / clinical candidates · MONDO_0018092

CTD chemicals (MyDisease.info)

7 associated chemicals · 25 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.

  • Atropine · therapeutic
  • Methylprednisolone · therapeutic
  • Mycophenolic Acid · therapeutic
  • prednisolone acetate · therapeutic
  • Prednisone · therapeutic
  • peginterferon alfa-2b · marker/mechanism
  • Ribavirin · marker/mechanism

Pathways: Cytokine-cytokine receptor interaction; PI3K-Akt signaling pathway; Toll-like receptor signaling pathway; NOD-like receptor signaling pathway; RIG-I-like receptor signaling pathway; Cytosolic DNA-sensing pathway; Jak-STAT signaling pathway; Natural killer cell mediated cytotoxicity

MyDisease.info · MONDO:0018092

Literature

Is anyone studying this?

3,343

3,343 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

3,343 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

1,758 in the last 10 years · low confidence

Phrase hits: 3,343 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

883

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Yang P16 papers · 2026

    The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Chongqing Key Laboratory of Ophthalmology, Chongqing, China; Chongqing Eye Institute, Chongqing, China; Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, China.. Electronic address: peizengycmu@126.com.

    Papers in Europe PMC
  2. 02
    Albloushi AF8 papers · 2026

    Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

    Papers in Europe PMC
  3. 03
    Herbort CP Jr8 papers · 2026

    Centre for Ophthalmic Specialized Care, Lausanne, Switzerland.

    Papers in Europe PMC
  4. 04
    Abu El-Asrar AM7 papers · 2026

    Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia. abuelasrar@yahoo.com.

    Papers in Europe PMC
  5. 05
    Su G6 papers · 2024

    The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, People's Republic of China.

    Papers in Europe PMC
  6. 06
    Bolletta E5 papers · 2026

    Ocular Immunology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

    Papers in Europe PMC
  7. 07
    Cimino L5 papers · 2026

    Ocular Immunology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

    Papers in Europe PMC
  8. 08
    Hayashi A5 papers · 2026

    Department of Ophthalmology, International University of Health and Welfare Hospital, Tochigi 327-2763, Japan.

    Papers in Europe PMC
  9. 09
    Imaizumi S5 papers · 2026

    Department of Ophthalmology, Imaizumi Eye Hospital, Koriyama, Japan.

    Papers in Europe PMC
  10. 10
    Muto T5 papers · 2026

    Department of Ophthalmology, Imaizumi Eye Hospital, Koriyama, Japan.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

5

interventional trials for this specific condition

5 interventional trials matched this specific condition name; 1 currently recruiting in our sample.

Data as of 11 September 2026

5 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 89.2th percentile).

low confidence · 89.2th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

5 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

5 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Vogt-Koyanagi-Harada disease — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Vogt-Koyanagi-Harada disease" OR "Uveomenigitic syndrome" OR "Harada's disease" OR "Vogt-Koyanagi syndrome" OR "uveomeningoencephalitic syndrome"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Vogt-Koyanagi-Harada disease" OR "Uveomenigitic syndrome" OR "Harada's disease" OR "Vogt-Koyanagi syndrome" OR "uveomeningoencephalitic syndrome"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 5 interventional · 5 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (3343) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-26T23:10:55.892Z